Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly - A meta-analysis.
Margit SolymárIvan IvicLászló PótóPéter HegyiAndrás GaramiPetra HartmannErika PéterváriLászló CzopfAlizadeh HussainZoltán GyöngyiPatrícia SarlósMária SimonPéter MátraiBálint BércziMárta BalaskóPublished in: PloS one (2018)
Our meta-analysis of RCTs showed a small reduction of body weight together with slight improvement of the blood lipid profile in patients over 60 years. With regard to the risk of unintentional weight loss, metformin seems to be a safe agent in the population of over 60 years. Our results also suggest that metformin treatment may reduce the risk of major coronary events (-4-5%) and all-cause mortality (-2%) in elderly diabetic populations.
Keyphrases
- body weight
- systematic review
- weight loss
- end stage renal disease
- newly diagnosed
- middle aged
- chronic kidney disease
- type diabetes
- coronary artery disease
- prognostic factors
- community dwelling
- low density lipoprotein
- heart failure
- meta analyses
- skeletal muscle
- wound healing
- combination therapy
- case control
- left ventricular
- atrial fibrillation